CPS Renal Mass (2018)
Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of renal mass and localized renal cancer..
Target Audience
- Urologists
- Residents
Learning Objectives
Upon completion of this course, participants will be able to:
- Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline.
- Perform appropriate methods of evaluation and management according to the guideline.
- Analyze the risks and benefits for treatment according to the guideline.
- Integrate AUA guidelines into clinical practice.
Faculty Disclosures
Authors:
Peter E. Clark: Galil Medical: Consultant or Advisor; Genentech: Consultant or Advisor
Planner Disclosures
Education Council:
Timothy Charles Brand, M.D. | Nothing to disclose | |
Anthony A. Caldamone MD | Nothing to disclose | |
Matthew S. Christman MD | Nothing to disclose | |
John D. Denstedt MD | Cook Urology | Owner, Product Development |
Endourological Society | Leadership Position | |
Endourological Society | Health Publishing | |
Interface Biologics | Consultant or Advisor | |
Jody Donaldson | Nothing to disclose | |
Shelby Englert | Nothing to disclose | |
Allen Gao MD, PhD | Pandomedx | Leadership Position, Owner, Product Development |
Matthew Thomas Gettman, M.D. | COVR Medical | Consultant or Advisor |
Intuitive Surgical | Consultant or Advisor | |
Exact Sciences | Scientific Study or Trial | |
Howard B. Goldman, MD | allergan | Consultant or Advisor |
Medtronic | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Cook | Scientific Study or Trial | |
Nuvectra | Consultant or Advisor | |
Axonics | Consultant or Advisor | |
NewUro | Consultant or Advisor | |
William C. Huang, MD | Photocure | Scientific Study or Trial |
Karl Storz | Scientific Study or Trial | |
William C. Hulbert Jr. MD | Nothing to disclose | |
Brant Inman, M.D., MS, FRCSC | Dendreon | Scientific Study or Trial |
Abbott Laboratories | Scientific Study or Trial | |
Genentech Inc | Scientific Study or Trial | |
Combat Medical | Consultant or Advisor, Scientific Study or Trial | |
FKD Therapies | Scientific Study or Trial | |
BioCancell | Consultant or Advisor | |
Nucleix | Scientific Study or Trial | |
Urogen | Scientific Study or Trial | |
Mark L. Jordan MD,FACS | Nothing to disclose | |
Martin A. Koyle MD | B | |
Yair Lotan ,MD | abbott | Scientific Study or Trial |
Cepheid | Consultant or Advisor, Scientific Study or Trial | |
Pacific Edge | Scientific Study or Trial | |
FKD | Scientific Study or Trial | |
MDxHealth | Consultant or Advisor, Scientific Study or Trial | |
biocancell | Scientific Study or Trial | |
Genomic Health | Scientific Study or Trial | |
GenomeDx Biosciences Inc | Scientific Study or Trial | |
photocure | Consultant or Advisor, Scientific Study or Trial | |
Nicole Lara Miller ,MD | Boston Scientific Corporation | Consultant or Advisor, Meeting Participant or Lecturer |
Practical Reviews In Urology | Health Publishing | |
Manoj Monga, MD, FACS | Fortec | Other |
Curtis Nickel, MD | Farr Laboratories | Consultant or Advisor |
Tribute | Consultant or Advisor | |
Aquinox | Scientific Study or Trial | |
GSK | Scientific Study or Trial | |
PureTech Health | Consultant or Advisor | |
AUA | Health Publishing | |
NIH | Scientific Study or Trial | |
Canadian Institute of Health Research | Scientific Study or Trial | |
Interface Biologics | Consultant or Advisor | |
Alvio Therapeutics | Consultant or Advisor | |
Seikagaku Corporation | Consultant or Advisor | |
Victor William Nitti MD | Astellas | Health Publishing, Scientific Study or Trial |
Allergan | Health Publishing, Scientific Study or Trial | |
Serenity Pharmeuticals | Investment Interest | |
Cook Myosite | Scientific Study or Trial | |
Medtronic | Scientific Study or Trial | |
Christopher Porter, MD | Nothing to disclose | |
Ganesh V. Raj MD, PhD | Ptares | Owner, Product Development |
C-diagnostics corp | Consultant or Advisor, Investment Interest | |
amgen | Meeting Participant or Lecturer | |
Johnson and Johnson | Consultant or Advisor, Owner, Product Development | |
Astellas | Meeting Participant or Lecturer | |
ASTELLAS | Consultant or Advisor, Meeting Participant or Lecturer | |
Janssen | Owner, Product Development | |
BAYER | Consultant or Advisor, Meeting Participant or Lecturer | |
SANOFI | Consultant or Advisor, Meeting Participant or Lecturer | |
GaudiumRx | Leadership Position, Investment Interest, Owner, Product Development | |
Medivation | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
EtiraRx | Leadership Position, Investment Interest, Owner, Product Development | |
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest |
Pacific Edge Biotechnology | Consultant or Advisor, Scientific Study or Trial | |
Lee Richstone, MD | Nothing to disclose | |
Heather Schultz, NP | SUNA | Meeting Participant or Lecturer |
SUNA | Leadership Position | |
Karl-Dietrich Sievert | AMS | Meeting Participant or Lecturer |
Medtronics | Meeting Participant or Lecturer, Scientific Study or Trial | |
Allergen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | |
Neotract | Meeting Participant or Lecturer | |
Stimguard | Meeting Participant or Lecturer, Scientific Study or Trial | |
Joseph A. Smith Jr.,MD | Nothing to disclose | |
Ryan Patrick Terlecki, MD, FACS | American Medical Systems | Consultant or Advisor, Other |
Allergan | Scientific Study or Trial | |
Edouard John Trabulsi, MD, FACS | GenomeDx | Consultant or Advisor |
Method of Participation
Learners will participate in this interactive online educational activity by completing a pre-test, reading the AUA Guideline, complete the slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: January, 2018
Expiration Date: January, 2021
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
CME Information
For all inquiries regarding CME credit email: cme@AUAnet.org
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation